Oka, Tetsuo
Kurozumi, Kazuhiko
Shimazu, Yosuke
Ichikawa, Tomotsugu
Ishida, Joji
Otani, Yoshihiro
Shimizu, Toshihiko
Tomita, Yusuke
Sakaguchi, Masakiyo
Watanabe, Masami
Nasu, Yasutomo
Kumon, Hiromi
Date, Isao
Article History
Received: 19 April 2016
Accepted: 24 August 2016
First Online: 14 September 2016
Competing interests
: Momotaro-Gene Inc. holds the patents for Ad-REIC and is developing it as an anti-cancer therapeutic agent. Dr Kumon, Dr Nasu, and Dr Watanabe demonstrated the utility of the agent and also owns stocks in Momotaro-Gene Inc. Okayama University and Momotaro-Gene Inc. are working together for the development of the Ad-REIC agent. Okayama University received the GMP-grade Ad-REIC agent from Momotaro-Gene Inc. to perform clinical trials for the treatment of cancer patients. Okayama University also received research funds for the joint research. Dr Kumon is the Chief Science Officer of Momotaro-Gene Inc.